Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 2
2011 1
2013 1
2014 2
2016 1
2017 2
2018 5
2019 4
2020 4
2021 4
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Among authors: van dam pj. Nat Med. 2023 Dec;29(12):3271. doi: 10.1038/s41591-023-02312-9. Nat Med. 2023. PMID: 36944799 No abstract available.
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, Tyson C, Stanoeva D, Daelemans S, Rombouts M, Mariathasan S, Tea JS, Mousa K, Sharma S, Aleshin A, Banchereau R, Castellano D, Powles T. Szabados B, et al. Among authors: van dam pj. Eur Urol. 2022 Aug;82(2):212-222. doi: 10.1016/j.eururo.2022.04.013. Epub 2022 May 14. Eur Urol. 2022. PMID: 35577646 Clinical Trial.
Telehealth experiences of vulnerable clients living in Tasmania.
Van Dam PJ, Caney D, Turner RC, Griffin P, Dwyer M, Prior S. Van Dam PJ, et al. Aust J Rural Health. 2022 Apr;30(2):188-196. doi: 10.1111/ajr.12835. Epub 2022 Jan 25. Aust J Rural Health. 2022. PMID: 35076149 Free PMC article.
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.
Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. Awada G, et al. Among authors: van dam pj. Cancers (Basel). 2021 Jan 6;13(2):168. doi: 10.3390/cancers13020168. Cancers (Basel). 2021. PMID: 33418936 Free PMC article.
Can medical imaging identify the histopathological growth patterns of liver metastases?
Latacz E, van Dam PJ, Vanhove C, Llado L, Descamps B, Ruiz N, Joye I, Grünhagen D, Van Laere S, Dirix P, Mollevi DG, Verhoef C, Dirix L, Vermeulen P. Latacz E, et al. Among authors: van dam pj. Semin Cancer Biol. 2021 Jun;71:33-41. doi: 10.1016/j.semcancer.2020.07.002. Epub 2020 Jul 28. Semin Cancer Biol. 2021. PMID: 32735852 Review.
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B. Jansen Y, et al. Among authors: van dam pj. Cancer Immunol Immunother. 2020 Dec;69(12):2589-2598. doi: 10.1007/s00262-020-02618-4. Epub 2020 Jun 26. Cancer Immunol Immunother. 2020. PMID: 32591862 Free PMC article. Clinical Trial.
29 results